°øÁö : µµÄìÁõ±Ç°Å·¡¼Ò JASDAQ ½ºÅÄ´Ùµå ½ÃÀå ½Å±Ô »óÀå °ü·Ã ¾È³»

Global Information
ȸ»ç¼Ò°³ | ¹®ÀÇ | ºñ±³¸®½ºÆ®

Áß±¹ÀÇ ÀǾàǰ ¹× ÇコÄɾî Á¦Ç° ½ÃÀå

China Pharmaceuticals & Healthcare

¸®¼­Ä¡»ç Fitch Solutions, Inc.
¹ßÇàÁ¤º¸ ¿¬°£±¸µ¶ »óǰ ÄÚµå 940152
ÆäÀÌÁö Á¤º¸ ¿µ¹® 95 Pages
°¡°Ý
US $ 1,415 £Ü 1,599,000 PDF (Single User License) - Includes 3 FREE Quarterly Updates


Áß±¹ÀÇ ÀǾàǰ ¹× ÇコÄɾî Á¦Ç° ½ÃÀå China Pharmaceuticals & Healthcare
¹ßÇàÁ¤º¸ : ÆäÀÌÁö Á¤º¸ : ¿µ¹® 95 Pages

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹®¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹®¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Áß±¹¿¡¼­´Â ÀǾàǰ °¡°Ý ÀÎÇϸ¦ ¸ñÀûÀ¸·Î ÇÑ ±ÔÁ¦ º¯°æÀÌ ÁøÇàµÇ°í ÀÖÀ¸¸ç, ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19) ÆÒµ¥¹Í¿¡ µû¸¥ ¿¬±¸°³¹ß ÅõÀÚµµ È®´ëµÇ°í ÀÖ¾î ÀǾàǰ ½ÃÀå¿¡ À¯¸®ÇØÁö°í ÀÖ½À´Ï´Ù. ³Î¸® »ç¿ëµÇ°í ÀÖ´Â ÀǾàǰ °¡°Ý ÀÎÇϸ¦ ¸ñÀûÀ¸·Î ÇÑ ±ÔÁ¦ º¯°æÀº ½ÂÀÎ ÀýÂ÷ ½Å¼ÓÈ­¸¦ ÇâÇÑ ´ëó µî°ú ÇÔ²² Çõ½ÅÀûÀÎ ½Å¾à °³¹ßÀ» ÁöÁöÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

Áß±¹ÀÇ ÀǾàǰ ¹× ÇコÄɾî Á¦Ç° ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ¾÷°è Àü¸Á, 󹿾à, ƯÇã ÃëµæÀÌ ³¡³­ ÀǾàǰ, Á¦³×¸¯ ÀǾàǰ, OTC ÀǾàǰ ½ÃÀå ¿¹Ãø, ¾÷°è À§Çè, ¾à»ç ±ÔÁ¦, Á¦13Â÷ 5°³³â °èȹ ¿äÁ¡, ±â¾÷ °³¿ä µîÀÇ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

  • ÁÖ¿ä °ßÇØ
  • Covid-19ÀÇ ¿µÇâ
  • SWOT ºÐ¼®
  • ¾÷°è ¿¹Ãø
  • ÀǾàǰ ½ÃÀå ¿¹Ãø
  • ÇコÄɾî Á¦Ç° ½ÃÀå ¿¹Ãø
  • ó¹æ¾à ½ÃÀå ¿¹Ãø
  • ƯÇã ÃëµæÀÌ ³¡³­ ÀǾàǰ ½ÃÀå ¿¹Ãø
  • Á¦³×¸¯ ÀǾàǰ ½ÃÀå ¿¹Ãø
  • OTC ÀǾàǰ ½ÃÀå ¿¹Ãø
  • ÀǾàǰ ¹«¿ª ¿¹Ãø
  • ¾÷°è À§Çè/º¸»ó Áö¼ö
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Çõ½ÅÀûÀÎ ÀǾàǰ À§Çè/º¸»ó Áö¼ö
  • Çõ½ÅÀûÀÎ ÀǾàǰ À§Çè/º¸»ó Áö¼ö
  • ¾à»ç ±ÔÁ¦ ¹ßÀü
  • ¾à»ç ±ÔÁ¦ ¸®ºä
  • Á¦13Â÷ 5°³³â °èȹ ¿äÁ¡
  • ½ÃÀå °³¿ä
  • °æÀï »óȲ
  • ±â¾÷ °³¿ä
  • AstraZeneca
  • Bayer HealthCare
  • China Shijiazhuang Pharmaceutical Group(CSPC)
  • Eli Lilly(Lilly China)
  • GlaxoSmithKline
  • MSD
  • Merck KGaA
  • North China Pharmaceutical Corporation
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Shanghai Pharmaceuticals Holding Co
  • Sinopharm
  • Áß±¹ÀÇ Àα¸Åë°è Àü¸Á
  • ¿ë¾îÁý
  • Á¶»ç ¹æ¹ý
KSM 20.09.04

Key View: China's pharmaceuticals and healthcare landscape will continue to evolve over the coming years as authorities seek to meet the population's rising demand for healthcare. Crucially, China will continue to expand access to its universal healthcare scheme through reform and liberalisation of its healthcare sector, improving access for low and middle-income patients. Despite the positive developments, innovative drugmakers will continue to face numerous challenged in China, limiting the market's attractiveness. The economic slowdown in light of Covid-19, will put additional pressure on public budget and the government will be urged to implement further cost-saving measures.

Table of Contents

  • Key View
  • China Pharmaceuticals & Healthcare Covid-19 Impact
  • SWOT
  • Industry Forecast
  • Pharmaceutical Market Forecast
  • Healthcare Market Forecast
  • Prescription Drug Market Forecast
  • Patented Drug Market Forecast
  • Generic Drug Market Forecast
  • OTC Medicine Market Forecast
  • Pharmaceutical Trade Forecast
  • Industry Risk/Reward Index
  • Asia Pacific Innovative Pharmaceuticals Risk/Reward Index
  • Innovative Pharmaceuticals Risk/Reward Index
  • Regulatory Development
  • Regulatory Review
  • 13th Five-Year Plan: Key Points
  • Market Overview

Competitive Landscape

  • Company Profile
  • AstraZeneca
  • Bayer HealthCare
  • China Shijiazhuang Pharmaceutical Group (CSPC)
  • Eli Lilly (Lilly China)
  • GlaxoSmithKline
  • MSD
  • Merck KGaA
  • North China Pharmaceutical Corporation
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Shanghai Pharmaceuticals Holding Co
  • Sinopharm
  • China Demographic Outlook
  • Pharmaceuticals & Healthcare Glossary
  • Pharmaceuticals & Healthcare Methodology
Back to Top
ÀüÈ­ ¹®ÀÇ
F A Q